Adaptimmune Therapeutics (Nasdaq: ADAP) reported promising initial responses in patients dosed with NY-ESO SPEAR T-cells in a second tumor lifting the stock price $1.73 to close at $10.94.
Adaptimmune Therapeutics reports upbeat initial results
March 15, 2018 at 17:14 PM EDT
